Some science behind the scenes
Methylbenzodioxolylbutanamine is a closely related analogue of MDMA. It was tested by Alexander Shulgin and described in his book, PiHKAL (Phenethylamines i Have Known And Loved).
MBDB's duration is 4–6 hours, with noticeable after-effects lasting for 1–3 hours. It causes "mild, MDMA-like effects, such as lowering of social barriers and inhibitions, pronounced sense of empathy and compassion, mood lift, and mild euphoria". And brain damage.
MBDB is not internationally scheduled under the United Nations Convention on Psychotropic Substances. The thirty-second meeting of the WHO Expert Committee on Drug Dependence (September 2000) evaluated MBDB and recommended against scheduling
Although MBDB is both structurally and pharmacologically similar to MDMA, the limited available data indicate that its stimulant and euphoriant effects are less pronounced than those of MDMA. There have been no reports of adverse or toxic effects of MBDB in humans. Law enforcement data on illicit trafficking of MBDB in Europe suggest that its availability and abuse may now be declining after reaching a peak during the latter half of the 1990s. For these reasons, the Committee did not consider the abuse liability of MBDB would constitute a significant risk to public health, thereby warranting its placement under international control. Scheduling of MBDB was therefore not recommended.
Sweden, however, has declared it a health hazard and made it illegal.